Dubai, United Arab Emirates: October 16, 2011: Hundreds of healthcare professionals from across the Gulf have gathered in Dubai to take part in the UAE's third fully comprehensive cancer congress, which covered presentations on a wide range of diseases including breast cancer, lung cancer, gastro-intestinal cancer, liver cancer, blood cancer ...
Media
BRIDGEWATER, N.J., May 4, 2011 — Axcan Intermediate Holdings Inc. announces that, as of today, it is changing its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies focused on gastrointestinal diseases: Axcan and Eurand. Aptalis Pharma also has a new corporate logo ... 
Global Life Sciences Leader Burrill & Company and Kuwait Investment Authority-Backed Fund Officially Launch NewBridge Pharmaceuticals 
Dubai-UAE: 22. July, 2009 – NewBridge announces that is has entered into an exclusive license and supply agreement with Axcan Pharma for Pylera®, an innovative 3-in-1 capsule therapy for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers. 
NewBridge's Sancuso gets featured in Time Magazine. |